Breast cancer is the most common malignancy for women. Multiple oncogenes, tumor suppressor genes, sex steroid hormones and their receptors are involved in the genesis and development of breast cancer. Breast cancer is also a heterogeneous tumor including a variety of subtypes with different biological behaviors, clinicopathologic features and molecular characteristics. The responses to treatment and the prognosis of different subtypes of breast cancer are also markedly different. Triple negative breast cancer (TNBC) is a newly proposed subtype of breast cancer, with poor biological behaviors, high invasiveness and poor prognosis. It can not benefit from endocrine therapy and HER2targeted therapy due to the negative estrogen receptor (ER), negative progesterone receptor (PR) and negative human epidermal growth factor receptor2 (HER2) [1] . Therefore, TNBC is mainly treated by chemotherapy. Currently, the clinical study for TNBC mainly focuses on prognostic indicators and the selection of therapeutic drugs. In recent years, it has been showed that androgen and androgen receptor (AR) also play an important role in the genesis and development of breast cancer, but their effects in different subtypes of breast cancer are still unclear. In the present study, we investigated the expression of AR in TNBC, and explored its correlation with the clinicopathologic features and prognosis of TNBC.
窑Original Article窑 Breast cancer is the most common malignancy for women. Multiple oncogenes, tumor suppressor genes, sex steroid hormones and their receptors are involved in the genesis and development of breast cancer. Breast cancer is also a heterogeneous tumor including a variety of subtypes with different biological behaviors, clinicopathologic features and molecular characteristics. The responses to treatment and the prognosis of different subtypes of breast cancer are also markedly different. Triple negative breast cancer (TNBC) is a newly proposed subtype of breast cancer, with poor biological behaviors, high invasiveness and poor prognosis. It can not benefit from endocrine therapy and HER2targeted therapy due to the negative estrogen receptor (ER), negative progesterone receptor (PR) and negative human epidermal growth factor receptor2 (HER2) [1] . Therefore, TNBC is mainly treated by chemotherapy. Currently, the clinical study for TNBC mainly focuses on prognostic indicators and the selection of therapeutic drugs. In recent years, it has been showed that androgen and androgen receptor (AR) also play an important role in the genesis and development of breast cancer, but their effects in different subtypes of breast cancer are still unclear. In the present study, we investigated the expression of AR in TNBC, and explored its correlation with the clinicopathologic features and prognosis of TNBC.
A total of 137 TNBC patients with complete followup data who underwent surgical resection and did not undergo preoperative radiochemotherapy in Sun Yatsen University Cancer Center between January 2001 and November 2004 were enrolled in our study; 132 nontriple negative breast cancer (nonTNBC) patients who underwent surgical resection during the same period were randomly selected as the control. All patients were female aging from 2580 years old, with a median age of 49 years. All patients were finally diagnosed as breast cancer by postoperative pathology. The criterion of TNBC was ER, PR and HER2negative. HER2 with and + immunohistochemical staining was judged as negative expression; for the cases with ++ expression, further fluorescence in situ hybridization was performed to determine the negative or positive expression.
The specimens of breast cancer were fixed with 10% formaldehyde and routinely embedded with paraffin to make 4滋 m serial tissue sections, and then HE staining and immunohistochemical staining were performed. Immunohistochemical staining was carried out according to the instruction of ZYMED PV6000G Kit. Briefly, after deparaffinization and hydration, the tissue sections were heated for antigen repair and treated with 3% hydrogen peroxide methanol solution to suppress endogenous peroxidase activity. After antigens were blocked with goat serum, the sections were incubated with AR antibody (1:100 working concentration) overnight, second antibody and ABC compound were biotinylated, DAB coloration was performed followed by hematoxylin counterstaining and sealing. The sections were observed under light microscope. PBS which replaced the primary antibody and served as the negative control, and the known positive prostate cancer samples served as the positive control.
The cells in five high power fields were counted. The expression of AR in breast cancer tissues were assessed according to the percentage of positive cells and staining intensity: a percentage of positive cells of 臆 1% scored 0, > 1% 臆 25% scored 1, >25% 臆 50% scored 2, >50% 臆 75% scored 3, >75% scored 4; weak expression (+) with slight yellow staining or only individual cells were stained in yellow to brownyellow scored 1, strong expression (+++) with staining from brownyellow to brown scored 3, moderate expression (++) with staining intensity between weakly positive and strongly positive scored 2. Scores of staining intensity 伊 score of percentage of positive cells was the integrated score: a score of 逸2 represented positive result, and 臆1 represented negative result.
All data were analyzed with SPSS16.0 software. The 字 2 test was adopted to analyze the correlation between the positive rate of AR and the clinicopathologic parameters. The survival time was calculated from the date of final diagnosis. The KaplanMeier method was adopted for survival analysis, and the Cox risk model was adopted for multivariate analysis.
AR protein was expressed, mainly in cell nuclei with moderate intensity ( Figure 1A ), only in 38 of 137 TNBC patients. However, AR protein was expressed in 110 of 132 nonTNBC patients, mainly with strong intensity ( Figure 1B ). There was significant difference between these groups (字 2 = 83.963, < 0.001). The correlation between AR expression and the clinicopathologic parameters of TNBC and nonTNBC is shown in Table 1 . AR expression was correlated with the menorrheal status, histological grade and lymph node metastasis of the TNBC patients, but not correlated with the clinicopathologic parameters of nonTNBC patients.
Univariate analysis showed that the tumor size, lymph node metastasis, tumor stage, vascular invasion, and AR expression were correlated with 5year overall survival (OS) of TNBC patients (Table 2 ). Multivariate analysis showed that tumor size, lymph node metastasis, and AR expression were correlated with 5year OS of TNBC patients ( Figure 2 ), but not correlated with the 5year DFS and OS of nonTNBC patients (Table 4, Figure 3 ). ER and PR promote the genesis and development of breast cancer, and are associated with its prognosis. Clinically, they have been widely recognized to guide endocrine therapy of breast cancer [2] . However, the correlation between androgen as well as AR and breast cancer is still controversial. More and more basic and clinical studies have suggested that AR and androgen are closely associated with the genesis, development and prognosis of breast cancer. Moreover, clinical practice has proved that antiandrogen rescue therapy is effective for some advanced breast cancer patients who failed to routine endocrine therapy.
The effects of androgen and AR in breast cancer are still unclear. However, epidemiologic investigation and animal model showed that androgen is one of the etiologic factors for breast cancer. Kaaks . [3] found through a casecontrol study involving 1986 patients that the postmenopause women with high serum level of androgen had high risk for breast cancer. Tworoger . [4] found through a casecontrol study that the premenopause women with high serum level of androgen had high risk for breast cancer. If the serum levels of progesterone and/or estrogen were also increased simultaneously, the risk for breast cancer was even higher [4] . Wong . [5] found through an animal model that testosterone combined with estrogen could induce the occurrence of breast cancer; if flutamide was used to rivalry the effect of estrogen, breast cancer would not be induced. It has been reported that AR expression is correlated with the DFS and OS of patients with breast cancer. Bryan . [6] reported that AR expression was significantly correlated with the survival of breast cancer patients, even through the ER status was considered. Agoff . [7] analyzed AR expression and its significance in 69 ERnegative and 19 ERpositive breast cancer patients. Univariate analysis showed that AR expression was correlated with the DFS of ERnegative breast cancer patients ( = 0.049), but not correlated with the DFS of ERpositive breast cancer patients [7] . Gonzalez . [8] studied AR expression and it significance in 83 breast cancer patients, and found that AR expression was significantly correlated with the OS of breast cancer patients ( = 0.001). In our study, univariate analysis showed that AR expression, vascular invasion, primary tumor size, lymph node metastasis and tumor stage were significantly showed that AR expression was not correlated with the DFS and OS of nonTNBC patients. The effect of AR expression on the DFS of breast cancer patients in our study is consistent with the results of Agoff . [7] , but its effect on OS was inconsistent between the two studies. The possible reasons of the inconsistence are as follows: both ERnegative breast cancer and TNBC are ERnegative, therefore there are some similarities between these two types; but both PR and HER2 are negative in TNBC, therefore, its biological behaviors and prognosis are worse. In addition, the small sample size in the latter study may also contribute to the inconsistence. The effect of AR expression on the OS of breast cancer patients in our study is consistent with the results of Gonzalez . [8] , however, our results showed that AR expression was mainly correlated with the DFS and OS of TNBC patients, but not nonTNBC patients.
It has been reported that AR expression is correlated with the prognosis of breast cancer . KuenenBoummeester . [ 9] analyzed the correlation between AR expression and the clinicopathologic features through detecting AR expression in 153 breast cancer patients. Univariate analysis showed that AR expression was an important prognostic factor for breast cancer, while multivariate analysis showed that only lymph node metastasis, tumor size and ER status were the independent prognostic factors for breast cancer [9] , which was consistent with our results. Differing from the results of KuenenBoummeester .
[9] , we did not find the significant correlation between AR status and Ki67 status, although a correlation trend was found. Isola . [10] found that AR expression was significantly correlated with tumor grade. Narita .
[11] studied AR expression and its significance in 156 female breast cancers, and found that AR expression was correlated with the pathologic type ( = 0.001), histological grade ( = 0.007) and lymph node metastasis ( = 0.002) of breast cancer. Our results showed that AR expression was correlated with the histological grade and lymph node metastasis of breast cancer, which is consistent with the literature. Bryan [6] found that AR expression was not correlated with menorrheal status, while we found that AR expression was significantly correlated with menorrheal status. These differences may be due to that most patients in our study were TBNC patients. Our study mainly focused on TBNC because TNBC has poor prognosis as compared with nonTNBC, and TNBC can not benefit from antiestrogen therapy and HER2targeted therapy. Our study showed that TNBC could be divided into good prognosis subtype and poor prognosis subtype according to AR status. Poor prognosis subtype may need more active postoperative treatment. The shortcomings of the present study are as follows: this was a retrospective study; some TNBC patients were lost to followup, and not all nonTNBC patients in the same period were included in our study.
In summary, the positive rate of AR in TNBC patients is about 30%, and AR expression is significantly correlated with the clinicopathologic features and prognosis of TNBC. TNBC could be further divided into good and poor prognosis subtypes according to AR expression. ARpositive patients could benefit from endocrine therapy. However, AR expression has no correlation with the clinicopathologic features and prognosis of nonTNBC. Whether AR expression is an important prognostic factor and whether it is correlated with the clinicopathologic features and prognosis of nonTNBC still require prospective studies with large sample sizes. Time (months)
